TrialAnnals of medicine2023

Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial.

Ziqi Wan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.